- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...
Upadacitinib is not approved for pediatric IBD, though the selective JAK1 inhibitor is indicated for patients 2 years and older with juvenile idiopathic arthritis and psoriatic arthritis. The findings ...
AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ ...
NORTH CHICAGO, Ill., Aug. 21, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating ...
MedPage Today on MSN
Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief
Trial data suggest a JAK inhibitor beats the leading biologic ...
AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback